Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer
Authors
Keywords
-
Journal
JAMA Oncology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2021-08-12
DOI
10.1001/jamaoncol.2021.2915
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
- (2020) E. Martinelli et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
- (2020) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?
- (2020) Giulia Martini et al. CANCER TREATMENT REVIEWS
- Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
- (2020) Toshiki Masuishi et al. BRITISH JOURNAL OF CANCER
- Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
- (2020) Morena Fasano et al. ESMO Open
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer
- (2019) G Siravegna et al. ANNALS OF ONCOLOGY
- Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
- (2019) Vitiello et al. Cancers
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer
- (2018) Chiara Cremolini et al. JAMA Oncology
- Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
- (2018) Alexander Stein et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
- (2018) C M Parseghian et al. ANNALS OF ONCOLOGY
- Product review: avelumab, an anti-PD-L1 antibody
- (2018) Julie M. Collins et al. Human Vaccines & Immunotherapeutics
- Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies
- (2018) Gianluca Mauri et al. CANCER TREATMENT REVIEWS
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
- (2012) D. Santini et al. ANNALS OF ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now